Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Lemos, R; Areias-Marques, S; Ferreira, P; O'Brien, P; Beltran-Jaunsaras, ME; Ribeiro, G; Martin, M; Del Monte-Millan, M; Lopez-Tarruella, S; Massarrah, T; Luis-Ferreira, F; Frau, G; Venios, S; McManus, G; Oliveira-Maia, AJ.

A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol

BMC Psychiatry. 2022; 22(1): Nº de citas: 8 [doi:10.1186/s12888-022-04446-5]

Argiles, G; Mulet, N; Valladares-Ayerbes, M; Vieitez, JM; Gravalos, C; Garcia-Alfonso, P; Santos, C; Tobena, M; Garcia-Paredes, B; Benavides, M; Cano, MT; Loupakis, F; Rodriguez-Garrote, M; Rivera, F; Goldberg, RM; Cremolini, C; Bennouna, J; Ciardiello, F; Tabernero, JM; Aranda, E; Tabernero, J.

A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

EUROPEAN JOURNAL OF CANCER. 2022; 177: 154-163 Nº de citas: 19 [doi:10.1016/j.ejca.2022.09.037]

Valladares-Ayerbes, M; Garcia-Alfonso, P; Luengo, JM; Caceres, PPP; Trujillo, OAC; Vidal-Tocino, R; Llanos, M; Ayala, BL; Miron, MLL; Salud, A; Nogueras, LC; Garcia-Carbonero, R; Safont, MJ; Ferrer, EF; Aparicio, J; Conesa, MAV; Guillen-Ponce, C; Garcia-Teijido, P; Magan, MBM; Busquier, I; Salgado, M; Vila, AL; PERSEIDA Investigators.

Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

Cancers. 2022; 14(24): Nº de citas: 7 [doi:10.3390/cancers14246075]

Bofill, JS; Anton, FM; Sanchez, CAR; Calvo, EG; Melia, CH; Gil, EMC; Vidal, M; Jimenez-Rodriguez, B; Merino, LD; Janez, NM; Vazquez, RV; Salas, RD; Torres, AA; Lopez, IMA; Gregori, JG; Garcia, VQ; Rubio, EV; De la Haba-Rodriguez, J; Gonzalez-Santiago, S; Fernandez, ND; Molins, AB; De Ibarguen, BCS; Mingorance, JID; Ezquerra, MB; De Casa, S; Gimeno, A; Martin, M.

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

BREAST. 2022; 66: 77-84 Nº de citas: 5 [doi:10.1016/j.breast.2022.09.006]

Schettini, F; Venturini, S; Giuliano, M; Lambertini, M; Pinato, DJ; Onesti, CE; De Placido, P; Harbeck, N; Lueftner, D; Denys, H; Van Dam, P; Arpino, G; Zaman, K; Mustacchi, G; Gligorov, J; Awada, A; Campone, M; Wildiers, H; Gennari, A; Tjan-Heijnen, V; Bartsch, R; Cortes, J; Paris, I; Martin, M; De Placido, S; Del Mastro, L; Jerusalem, G; Curigliano, G; Prat, A; Generali, D.

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

CANCER TREATMENT REVIEWS. 2022; 111: Nº de citas: 28 [doi:10.1016/j.ctrv.2022.102468]

Taboada AGM; Lominchar PL; Martínez MF; García-Alfonso P; Martin AM; Asencio JM.

Neoadjuvant therapy impact in early pancreatic cancer: "bioborderline" vs. "non-bioborderline".

Annals of Hepato-Biliary-Pancreatic Surgery. 2022; 26(4): 363-374 Nº de citas: 1 [doi:10.14701/ahbps.22-023]

Villanueva-Bueno C; Collado-Borrell R; Escudero-Vilaplana V; Revuelta-Herrero JL; Marzal-Alfaro MB; González-Haba E; Arranz-Arija JÁ; Osorio S; Herranz-Alonso A; Sanjurjo-Saez M.

A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital.

Frontiers in Public Health. 2022; 10: 978783-978783 Nº de citas: 4 [doi:10.3389/fpubh.2022.978783]

Vera, R; Ibarrola-de-Andres, C; Adeva, J; Perez-Rojas, J; Garcia-Alfonso, P; Rodriguez-Gil, Y; Macarulla, T; Serrano-Pinol, T; Mondejar, R; Madrigal-Rubiales, B.

Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

Clinical & Translational Oncology. 2022; 24(11): 2107-2119 Nº de citas: 4 [doi:10.1007/s12094-022-02873-0]

Climent, MA; Font, A; Duran, I; Puente, J; Mendez-Vidal, MJ; Saez, MI; Lobera, CS; Arija, JAA; Gonzalez-Del-Alba, A; Sanchez-Hernandez, A; Fita, MJJ; Esteban, E; Alonso-Gordoa, T; Gonzalez, BM; Maroto, P; Lazaro-Quintela, M; Cassinello-Espinosa, J; Perez-Valderrama, B; Garcias, C; Castellano, D.

A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

EUROPEAN JOURNAL OF CANCER. 2022; 175: 110-119 Nº de citas: 10 [doi:10.1016/j.ejca.2022.08.002]

de la Rosa, CA; Castellanos, PC; Lazaro-Quintela, M; Domine, M; Estevez, SV; Lopez-Vivanco, G; Perez, JLF; Romero, JLA; Delgado, LF; Giron, CG; Tain, PD; Alvarez, RA; Sanchis, PM; Canton, IF; Abos, IM; Aguillo, MM; Gutierrez, LGA; Granados, ALO; Cabellos, RA; Sebastian, AG; Sifuentes, LFG; Reguart, N.

Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

LUNG CANCER. 2022; 173: 83-93 Nº de citas: 10 [doi:10.1016/j.lungcan.2022.09.010]

Quinaglia T; Gongora C; Awadalla M; Hassan MZO; Zafar A; Drobni ZD; Mahmood SS; Zhang L; Coelho-Filho OR; Suero-Abreu GA; Rizvi MA; Sahni G; Mandawat A; Zatarain-Nicolás E; Mahmoudi M; Sullivan R; Ganatra S; Heinzerling LM; Thuny F; Ederhy S; Gilman HK; Sama S; Nikolaidou S; Mansilla AG; Calles A; Cabral M; Fernández-Avilés F; Gavira JJ; González NS; García de Yébenes Castro M; Barac A; Afilalo J; Zlotoff DA; Zubiri L; Reynolds KL; Devereux R; Hung J; Picard MH; Yang EH; Gupta D; Michel C; Lyon AR; Chen CL; Nohria A; Fradley MG; Thavendiranathan P; Neilan TG.

Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis

JACC-Cardiovascular Imaging. 2022; 15(11): 1883-1896 Nº de citas: 28 [doi:10.1016/j.jcmg.2022.06.014]

García Adrián S; Gonzalez, AR; De Castro, EM; Olmos, VP; Moran, LO; del Prado, PM; Fernandez, MS; Burón JDC; Escobar, IG; Galan, JM; Pérez AIF; Neria, F; Lavin, DC; Hernández BLSV; Jimenez-Fonseca, P; Muñoz Martín AJ.

Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis

European Journal of Internal Medicine. 2022; 105: 30-37 Nº de citas: 15 [doi:10.1016/j.ejim.2022.07.020]

Carmona-Bayonas, A; Verso, M; Canovas, MS; Perez, JR; de Herreros, MG; del Prado, PM; Perez, IF; Verduguez, TQ; Portero, BO; Olmos, VP; Gomez, D; Ortega, L; Moyano, MS; Brozos, EM; Biosca, M; Rebollo, MA; Sanchez, LT; Perez, CH; Buron, JDC; Lago, NM; Perez, EG; Langa, JM; Segura, PP; de Castro, EM; Jimenez-Fonseca, P; Agnelli, G; Munoz, A.

Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

THROMBOSIS AND HAEMOSTASIS. 2022; 122(10): 1653-1661 Nº de citas: 4 [doi:10.1055/a-1816-8347]

Lope, V; Guerrero-Zotano, A; Ruiz-Moreno, E; Bermejo, B; Antolin, S; Montano, A; Baena-Canada, JM; Vazquez, MR; de Larrea-Baz, NF; Chacon, JI; Garcia-Saenz, JA; Olier, C; Munoz, M; Anton, A; Rovira, PS; Lanza, AA; Gonzalez, S; Oltra, A; Brunet, J; Gregori, JG; Martinez, MT; Calvo, L; Rosell, L; Bezares, S; Pastor-Barriuso, R; Perez-Gomez, B; Martin, M; Pollan, M.

Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGEICAM Study

Cancers. 2022; 14(19): Nº de citas: 10 [doi:10.3390/cancers14194705]

Canovas, MS; Garay, DF; Moran, LO; Perez, JR; Rubio, CMG; de Mena, ML; Portero, BO; Castro, JB; Lage, Y; Lavin, DC; Blanco, ABR; de Soignie, AMMF; Perejon, JZB; Colomo, LJ; Boluda, NB; Moreno, JB; Verduguez, TQ; Garrido, CR; Huertas, RM; Puig, CFI; Martin, AJM.

Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group

Clinical & Translational Oncology. 2022; 24(10): 2010-2020 Nº de citas: 23 [doi:10.1007/s12094-022-02860-5]

Majem, M; Alvarez, R; Ortega, AL; de Alda, LR; Gordo, R; Garcia, JF; Ivanova-Markova, Y; Gonzalez-Dominguez, A; San Cristobal, RS; Rojo, F.

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain

Global & Regional Health Technology Assessment. 2022; 9: 82-90 Nº de citas: 2 [doi:10.33393/grhta.2022.2449]

Galactionova, K; Loibl, S; Salari, P; Marme, F; Martin, M; Untch, M; Bonnefoi, HR; Kim, SB; Bear, HD; McCarthy, N; Gelmon, KA; Garcia-Saenz, JA; Kelly, CM; Reimer, T; Toi, M; Rugo, HS; Gnant, M; Makris, A; Burchardi, N; Schwenkglenks, M.

Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

Frontiers in Oncology. 2022; 12: Nº de citas: 3 [doi:10.3389/fonc.2022.886831]

Vazquez, JC; Pinero, A; de Castro, FJ; Lluch, A; Martin, M; Barnadas, A; Alba, E; Rodriguez-Lescure, A; Rojo, F; Gimenez, J; Sola, I; Quintana, MJ; Bonfill, X; Urrutia, G; Sanchez-Rovira, P.

The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

Clinical & Translational Oncology. 2022; 24(9): 1744-1754 Nº de citas: 7 [doi:10.1007/s12094-022-02824-9]